Table 3.
CD44 signaling pathway polymorphisms and TTR and OS in patients with localized GA.
| Time to recurrence | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
| N | Median time to recurrence, yrs (95% CI) |
Hazard Ratio (95% CI) | P value * | Median overall survival, yrs (95% CI) |
Hazard Ratio (95% CI) | P value * | |
| CD44 rs8193 | 0.95 | 0.39 | |||||
| C/C | 45 | 2.2 (1.2, 10.7+) | 1 (Reference) | 4.1 (2.0, 10.7+) | 1 (Reference) | ||
| C/T | 62 | 2.3 (1.7, 7.0) | 0.97 (0.54, 1.76) | 5.5 (3.8, 12.3+) | 0.65 (0.32, 1.31) | ||
| T/T | 21 | 2.9 (1.7, 7.0+) | 0.88 (0.39, 1.95) | 4.5 (2.7, 5.7) | 0.95 (0.40, 2.25) | ||
| C/T, T/T | 83 | 2.3 (1.7, 7.0) | 0.95 (0.54, 1.66) | 0.85 | 4.7 (3.8, 7.3) | 0.72 (0.37, 1.39) | 0.32 |
| CD44 rs187115 | 0.79 | 0.75 | |||||
| T/T | 58 | 2.5 (1.7, 12.3+) | 1 (Reference) | 4.1 (3.3, 12.3+) | 1 (Reference) | ||
| C/T | 52 | 2.2 (1.7, 7.0) | 1.21 (0.68, 2.15) | 5.5 (3.4, 7.3) | 1.04 (0.53, 2.01) | ||
| C/C | 15 | 7.0+ (1.1, 7.0+) | 1.01 (0.41, 2.50) | 3.8 (1.2, 7.0+) | 1.41 (0.55, 3.60) | ||
| CD44 rs187116 | 0.033 | 0.096 | |||||
| A/A | 30 | 7.0 (4.4, 10.6+) | 1 (Reference) | 7.3 (3.8, 10.6+) | 1 (Reference) | ||
| A/G | 56 | 2.2 (1.5, 7.0) | 2.07 (0.95, 4.51) | 4.5 (3.3, 7.3) | 1.78 (0.76, 4.16) | ||
| G/G | 38 | 1.7 (1.1, 2.3) | 2.90 (1.25, 6.72) | 2.8 (2.4, 4.5) | 2.65 (1.05, 6.70) | ||
| A/G,G/G | 94 | 2.1 (1.5, 2.5) | 2.32 (1.10, 4.91) | 0.022 | 4.1 (3.3, 5.4) | 2.02 (0.90, 4.57) | 0.079 |
| CD44 rs4755392 | 0.59 | 0.77 | |||||
| T/T | 43 | 3.2 (1.2, 5.9+) | 1 (Reference) | 3.8 (2.8, 7.3+) | 1 (Reference) | ||
| A/T | 53 | 2.1 (1.6, 14.5+) | 1.05 (0.56, 1.99) | 4.1 (3.6, 14.6+) | 0.76 (0.35, 1.66) | ||
| A/A | 34 | 3.7 (2.1, 7.0) | 0.76 (0.37, 1.57) | 5.4 (2.8, 7.3) | 0.80 (0.36, 1.81) | ||
| A/T,A/A | 87 | 2.3 (1.8, 7.0) | 0.93 (0.51, 1.69) | 0.80 | 4.7 (3.8, 7.3) | 0.78 (0.38, 1.60) | 0.48 |
| CD44 rs7116432 | 0.10 | 0.024 | |||||
| G/G | 36 | 7.0 (2.1, 12.3+) | 1 (Reference) | 7.3 (5.4, 12.3+) | 1 (Reference) | ||
| A/G | 60 | 2.3 (1.3, 7.0) | 1.77 (0.90, 3.47) | 4.1 (3.3, 7.3) | 2.16 (0.97, 4.83) | ||
| A/A | 31 | 1.7 (1.0, 5.7+) | 2.19 (1.02, 4.71) | 3.8 (2.0, 5.7+) | 3.32 (1.32, 8.40) | ||
| A/G,A/A | 91 | 2.2 (1.4, 4.4) | 1.89 (1.00, 3.60) | 0.045 | 3.8 (2.8, 4.7) | 2.44 (1.13, 5.27) | 0.018 |
| OPN rs1126616 | 0.79 | 0.80 | |||||
| C/C | 59 | 2.2 (1.2, 12.3+) | 1 (Reference) | 4.1 (3.3, 12.3+) | 1 (Reference) | ||
| C/T | 42 | 2.3 (1.7, 7.0) | 0.96 (0.53, 1.75) | 4.7 (2.8, 7.3) | 0.81 (0.41, 1.62) | ||
| T/T | 24 | 7.0 (1.8, 7.0+) | 0.78 (0.37, 1.63) | 4.5 (3.8, 7.3+) | 0.81 (0.36, 1.86) | ||
| OPN rs9138 | 0.70 | 0.94 | |||||
| A/A | 61 | 2.2 (1.3, 12.3+) | 1 (Reference) | 5.5 (2.5, 12.3+) | 1 (Reference) | ||
| A/C | 43 | 2.3 (1.7, 7.0) | 0.99 (0.55, 1.77) | 4.7 (2.8, 7.3) | 0.92 (0.47, 1.82) | ||
| C/C | 27 | 7.0 (1.8, 7.0+) | 0.75 (0.37, 1.52) | 4.5 (3.8, 7.3+) | 0.88 (0.40, 1.94) | ||
| HAS2 rs4123220 | 0.38 | 0.25 | |||||
| A/A | 60 | 1.7 (1.2, 7.0) | 1 (Reference) | 4.1 (2.8, 5.7) | 1 (Reference) | ||
| A/T | 49 | 2.9 (1.8, 12.3+) | 0.68 (0.38, 1.21) | 4.5 (2.8, 12.3+) | 0.98 (0.52, 1.85) | ||
| T/T | 18 | 2.3 (1.5, 5.9+) | 0.72 (0.33, 1.59) | 7.3+ (2.8, 7.3+) | 0.38 (0.11, 1.28) | ||
| HAS2 rs1057308 | 0.29 | 0.17 | |||||
| A/A | 60 | 1.7 (1.5, 7.0) | 1 (Reference) | 4.1 (2.8, 5.7) | 1 (Reference) | ||
| A/G | 52 | 2.9 (1.8, 12.3+) | 0.66 (0.37, 1.16) | 4.5 (3.3, 12.3+) | 0.83 (0.45, 1.55) | ||
| G/G | 19 | 5.9+ (1.5, 5.9+) | 0.68 (0.31, 1.49) | 7.3+ (3.8, 7.3+) | 0.33 (0.10, 1.11) | ||
*
Based on the log-rank test
Abbreviations: CD44, cluster of differentiation 44; OPN, Osteopontin; HAS2, hyaluronan synthase 2